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ABSTRACT 
Tianeptine (37.5 mg/day) and paroxetine (20 mg/day) were compared in a population of 
depressive patients without past or current history of co-morbid anxiety and/or important 
anxiolytic treatment. In a 6-week, double blind trial, the special focus was on anxious symptoms. 
Both drugs showed good efficacy on depressive symptomatology, assessed with MADRS and 
HDRS, but no difference was detected between tianeptine and paroxetine, for any assessment 
criterion. Despite the choice of selected depressive patients, without any co-morbid anxious 
disorder, anxiety scale scores at inclusion (HAMA and BAS) were appreciable but correlated 
poorly with depressive scores. Both tianeptine and paroxetine improved the apparent anxious 
component in depression. Tolerability of both drugs was good, although significantly better with 
tianeptine. 
Thus tianeptine and paroxetine are effective and safe treatments for major depression and may 
also act directly on the anxious component of the psychopathology. 
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Tianeptine is an atypical tricyclic compound, for which antidepressant efficacy has been well 
established, particularly in comparison with amitriptyline (Lôo et al., 1988; Guelfi et al., 1989), 
imipramine (Cassano et al., 1996), fluoxetine (Alby et al., 1993; Lôo et al., 1999) and placebo 
(Cassano et al., 1996; Costa e Silva et al., 1997; Dalery et al., 2001). Preclinical and clinical 
studies suggest that it may have some anxiolytic properties in depressed patients. Paroxetine is 
also a well-known antidepressant, displaying anxiolytic properties (Boyer and Feighner, 1992; 
Foster and Goa, 1997). It was, therefore, interesting to compare these drugs both as regards 
their antidepressant efficacy, and their respective actions on the anxious component of 
depression. 
Depression and anxiety are frequently associated and have in common many symptoms and 
signs, as shown in epidemiological, co-morbidity studies (Lépine, 1994; Wittchen et al., 1994; 
Kessler et al., 1996; Maier and Falkai, 1999). Phenomenological studies have shown that the 
incidence of anxious symptoms in depression is high, namely 62-98% of depressive patients 
(Hamilton, 1989; Kuhs, 1991). Moreover, some authorities have suggested that a subtype of 
depression characterised by anxiety should be recognised. Some studies have reported a poorer 
outcome and response to antidepressant medication for this syndrome than for 'pure' 
depression (Andreasen et al., 1980; Kravitz et al., 1989). However, current classifications do not 
as yet include a separate category of depression based on anxiety symptoms, as many other 
studies have failed to show specific characteristics for these 'anxious depressions', especially 
with respect to prognosis (Joffe et al., 1993). But, beside specific depressive disorders and 
anxiety disorders, a mixed anxiety/depressive disorder may exist (Sartorius et al., 1996; 
Boulenger et al., 1997; Wittchen et al., 2001) and diagnostic criteria for clinical research are 
provided in the DSM-IV classification (American Psychiatric Association, 1994). 
The ICD-10 (World Health Organization, 1993) classification acknowledges its existence and 
apparently high incidence. This symptomatic overlap may also be observed in the assessment 
tools used for the measurement of anxiety and depression (Watson et al., 1995a,b). The 
measurement of depressive symptom patterns is quite simple from a methodological point of 
view. However, measurement of efficacy on the anxious symptoms of depression leads to 
difficult methodological problems. In fact, while depression and anxiety clearly differ as 
symptoms, it is difficult to distinguish the syndromes or the mental disorders of which they are 
characteristic features. The main problem stems from the fact that statistical correlations 
between depression and anxiety rating scales in different clinical and non-clinical populations 
are often surprisingly high (Wetzler and Katz, 1989; Clark and Watson, 1991; Watson et al., 
1995a,b). Consequently, the combined use of depression and anxiety tools is not necessarily a 
valid approach for distinguishing an anxiolytic effect from an antidepressant one (Wetzler and 
Katz, 1989): multivariate analysis may provide more specific depression and anxiety 
instruments (de Bonis et al., 1991; Martinsen et al., 1989). 
Further, to the question of the relationship between depression and anxiety from a nosological 
and diagnostic point of view, treatments for depression should also be found effective in 
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relieving anxious symptoms in depressive patients, as they are common, painful and potentially 
associated with a higher suicide risk (Fawcett, 1997; Maier and Falkai, 1999). 
The present study had two aims. The first was to compare the antidepressant efficacy of 
tianeptine to that of paroxetine in the treatment of patients with a major depressive episode. 
Safety data were also recorded in order to compare the tolerability of the compounds. 
The second aim was to evaluate the effectiveness of tianeptine versus paroxetine on anxiety in 
these patients. Since anxious symptoms seem so frequent in patients with any depressive 
disorder, this study aimed to evaluate major depressive episodes as 'pure' as possible, and not in 
a selected sample of particularly anxious, depressed individuals. The preliminary correlations 
observed between depression and anxiety scales suggested that this evaluation could be made 
either directly through the anxiety scales used in the study, or after factorial analysis of all the 
assessment tools used in the study, with post hoc identification of anxiety-related clusters. 
The present publication presents the efficacy results of the study (antidepressant and anxiolytic 
actions) and tolerability of the two compounds. Specific methodological aspects of this trial, 
including the possible overlap in assessment tools for measurement of anxiety and depression 
and correlations between antidepressant and anxiolytic effects, will be presented separately in 
detail elsewhere. 
Methods 
This multicentre, international, double-blind study was conducted in eight countries: France (20 
centres), Belgium (seven centres), Spain (five centres), Hungary (four centres), United Kingdom 
(three centres), Italy (three centres), Switzerland (one centre) and Portugal (one centre). All 
investigators were experienced psychiatrists except in the United Kingdom (some investigators 
were general practitioners with a special training and interest in psychiatric disorders). 
The trial was conducted according to the principles in the Declaration of Helsinki and in its latter 
revisions, and to the rules of European Good Clinical Practices. The initial protocol, the single 
amendment (for Hungary only) and consent forms in national languages were submitted either 
to national or local ethics committees, according to national legislation. All patients gave written 
consent for participation in the study. The clinical part of the study was conducted between 
November 1997 and May 1999. 
PATIENT SELECTION 
Male or female, in- or outpatients, aged from 18 to 65 years, fulfilling DSM-IV criteria for Major 
Depressive Disorder (single episode or recurrent, severity moderate to severe, without 
psychotic features, with or without melancholic features and, for recurrent disorders, with or 
without seasonal pattern and interepisode recovery), were eligible for the study. 
To be selected, patients had to present at D7 a minimum severity score of 25 on the 
Montgomery-Asberg depression rating scale (MADRS) and of nine on the unidimensional 
subscale of the Hamilton depression rating scale (HDRS, items 1, 2, 7, 8, 10 and 13). These 
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severity criteria also had to be present at inclusion, and those patients with a decrease of 30% or 
more on MADRS or HDRS global scores were excluded. 
Patients fulfilling DSM-IV criteria for other Major Depressive Disorders: Bipolar I or II Disorders 
(past or present), dysthymic disorder, cyclothymic disorder, mixed anxio-depressive disorder, 
recurrent brief depressive disorder, schizophrenia or any other acute or chronic psychosis (past 
or present) and patients whose present disorder was due to a general medical condition or to a 
substance were not eligible for the study. 
Particular interest was focussed on any history of anxious disorders: patients with a lifetime 
diagnosis (DSM-IV criteria) of anxiety disorder - panic disorder, agoraphobia, specific phobia, 
social phobia, obsessive-compulsive disorder or acute stress disorder - except generalised 
anxiety disorder were excluded from the trial. Patients having presented any diagnosis of 
'depression plus anxiety' or generalised anxiety disorder within the last year could not be 
included either. Similarly, special attention was paid to previous anxiolytic treatments. 
Treatments with a benzodiazepine during the last 2 weeks, or for more than 1 month during the 
last 6 months, or at a daily dose equal to or greater than an equivalent of 15 mg of diazepam on a 
lifetime period, were also non-inclusion criteria. 
In addition, the following patients were excluded: non-responders to a previous treatment with 
paroxetine or tianeptine, those defined as non-responders for the current depressive episode (at 
least two successive well-conducted treatments), any considered at risk of suicide, those 
incapable of complying with the requirements of the protocol, those with any severe or 
uncontrolled somatic disease (investigator's judgement), a history of alcohol or drug abuse or 
dependence, pregnant or breast feeding women, women of child-bearing potential without 
effective contraception and any who had participated in another clinical study within the last 
three months or had previously been included in the present study. Patients who had recently 
(<3 months) initiated or altered treatment with thyroid hormones or, β-blockers, requiring 
electro-convulsive therapy or antiepileptic treatment or any CNS-active drug during the study 
period (such as corticosteroids, ACTH, central α-compounds, reserpine, methyldopa or 
sumatriptan) could not be recruited into the study. 
Patients also could not be included if they had been treated with a depot neuroleptic less than 2 
months previously, with fluoxetine, non-selective MAOI, lithium, valproate or carbamazepine 
during the previous month or with any other antidepressant drug during the week before the 
trial. 
STUDY DESIGN 
At selection visit (D7), after giving written, informed consent, patients underwent a complete 
medical and psychiatric evaluation, with verification of DSM-IV criteria for major depression and 
MADRS and HDRS assessments. Self-rating scales (severity of depression questionnaire - QSD; 
hospital anxiety and depression scale - HAD; mood and anxiety symptom questionnaire - MASQ 
and visual analogue scales - VAS) were also used at selection. 
Selected patients then entered a 7-day, run-in, placebo period, which could be shortened to 3 
days, depending on the clinical status of the patients. 
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Patients were also evaluated at inclusion (D1), during the double-blind treatment period (D3, 
D7, D14, D28 and D42) and 7 days after treatment cessation (post visit). The interval between 
visits had to be adhered to, within a range of ±3 (D7 and D14) or 6 days (D28 and D42). 
After the D42 visit, depending on the patient's condition, the investigators could either stop the 
treatment (with a post visit 7 days after for evaluating possible withdrawal symptoms) or 
continue for up to 6 months (optional period). No evaluation was made during the optional 
period, except for pharmacovigilance data. At the end of the 6-month optional period, a post-
visit could be made but was not mandatory. 
The main efficacy criterion was the MADRS global score (extracted from the comprehensive 
psychiatric rating scale - CPRS, except at the selection visit). Other efficacy criteria were 
observer rating scales: HDRS, HAMA, CPRS (out of which was extracted the brief anxiety scale - 
BAS), the clinical global impression (CGI) and self-rating scales (QSD, HAD, MASQ and six VAS). 
Tolerability was assessed by monitoring of adverse events and by using the Arbeitsgemeinschaft 
für Methodik und Dokumentation Psychoatrischer befunde scale (AMDP-5). The supplement 
Check Lists d'Evaluation des Symptomes Somatiques (CHESS supplement) was used at the post 
visit in order to look for possible withdrawal syndromes. Compliance (including morning 
compliance) was assessed at each visit throughout the study by counting the remaining capsules 
returned by the patients. 
ASSESSMENT TOOLS 
In order to assess accurately the symptom levels, both depression (MADRS and HDRS) and 
anxiety scales (BAS and HAMA) were used as assessment tools (with MADRS as main efficacy 
criteria). However, these scales are limited in that they do not evaluate all possible aspects of 
anxiety and depression but only selected dimensions. Moreover, the anxiety scales have been 
designed to evaluate anxiety in anxious patients, and their validity in depression can only be 
assumed. Therefore, a general psychopathology scale was incorporated in order to assess other 
possible dimensions. For practical reasons, CPRS was chosen as the general psychopathology 
scale, as it includes both MADRS and BAS. The protocol also stated the intention to study 
independence between anxiety and depression scales by assessing correlation at inclusion. 
Other assessment tools used were CGI, as a simple and reliable general scale, and self-evaluation 
scales (QSD, HAD, MASQ and visual self-rating scales) for evaluating any possible discrepancies. 
STATISTICAL METHODOLOGY 
Analysis of the efficacy data was performed both on the intention to treat population (ITT: all 
patients with at least one evaluation under treatment) and on the per protocol population (PP: 
all completed patients without major deviation, according to the study protocol). The analysis 
was done at end-point for the ITT population and visit by visit for the PP population. 
The analysis of safety data used all patients who had taken at least one dose of randomised 
treatment. 
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Across the 58 active centres, 366 patients were selected and 327 included (FRA: 146, HUN: 55, 
GBR: 39, BEL: 38, ESP: 21, CHE: 15, ITA: 9, POR: 4), 162 in the tianeptine group and 165 in the 
paroxetine group. Out of these, 16 (eight in each group) were considered to deviate markedly 
from the inclusion criteria (major deviation). 
Out of the 269 patients who completed the study up to D42, 133 were in the tianeptine group 
and 136 in the paroxetine group, and six were considered to present a major deviation (T = 2, P 
= 4). The 58 premature withdrawals split equally between each group (T = 29, P = 29). The 
intent-to-treat (ITT) population included 317 patients (T = 157, P = 160) and the per-protocol 
(PP) population comprised 256 patients (T = 127, P = 129). 
COMPARABILITY AT BASELINE 
Comparability at baseline between treatment groups was assessed, both for demographic 
variables (Table 1) and for evaluation criteria (Table 2). The only statistically significant 
difference between treatment groups was for the number of previous depressive episodes. 
Table 1. Comparability at baseline (demographic and clinical criteria)a 
Criteria  Tianeptine (n = 162) Paroxetine (n = 165) 
Age (yr)   
  Mean ± S.D. 41 ± 10 42 ± 12 
  Range [19-65] [18-64] 
Sex ratio (%): M/F 27/73 22/78 
Hospitalised patients (%) 17 20 
Previous psychotropic treatment (%) 67 68 
Single episode, moderate (%) 30 30 
Single episode, severe (%) 8 10 
Recurrent depression, moderate (%) 42 41 
Recurrent depression, severe (%) 20 19 
Number of previous episodes 
(for recurrent patients only)* 
2.2 ± 1.7 2.8 ± 2.7 
DSM-IV criteria for melancholia (%) 40 37 
aAll differences NS except *: p = 0.034. 
Table 2. Comparability at baseline (ITT population)a 
Criteria  Tianeptine (n = 157) Paroxetine (n = 160) 
MADRS global score 31.5 ± 4.9 34.4 ± 4.9 
HDRS global score 27.4 ± 4.7 27.1 ± 4.6 
HAMA global score 24.4 ± 7.2 24.1 ± 7.2 
BAS global score 18 ± 6.4 18.4 ± 6.6 
aAll differences NS. 
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Table 3. Evaluation of efficacy at end point (ITT population)a 
Criteria  Tianeptine (n = 157) Paroxetine (n = 160) 
MADRS global score 13.5 ± 10.3 13.3 ± 10.8 
HDRS global score 12.7 ± 8.5 12.4 ± 8.7 
HAMA global score 11.8 ± 8.5 11.6 ± 8.5 
BAS global score 8.5 ± 6.5 8.9 ± 7.2 
aAll differences NS. 
CLINICAL EFFICACY 
Depression scales. In the ITT population, mean MADRS and HDRS global scores decreased 
significantly between inclusion and end point (p < 0.001). None of these scales differed 
significantly between groups (Table 3). 
The mean MADRS global score (main criterion) decreased between D1 and end point from 31.5 
to 13.5 in the tianeptine group and from 31.4 to 13.3 in the paroxetine group (p = 0.826 at end 
point). 
Response to treatment, defined as at least a 50% decrease in inclusion score, was high with both 
treatments (more than 60%), without significant differences between groups, either on MADRS 
(T = 96 [61%], P = 108 [68%], p = 0.930) or HDRS (T = 96 [61%], P = 105 [66%], p = 0.915). 
All these results were confirmed in the PP population. No significant difference was observed at 
D42 and time course evolutions were very similar between groups (Figures 1 and 2). 
Anxiety scales. In the ITT population, mean HAMA and BAS global scores also decreased 
significantly between inclusion and end point (p < 0.001). No significant difference between 
groups was observed (Table 3). These results were confirmed in the PP population. No 
significant difference was observed between groups at D42 and, again, the time courses were 
very similar (Figure 3). 
Other scales. Global assessments (CGI) and data from the different self-rating scales (QSD/R, 
HAD depression, HAD anxiety, six sub-scales of MASQ and six VAS) confirmed these 
observations. None of these measures showed any significant difference, with, generally, very 
similar results between groups. 
MADRS scores 
 
Figure 1. Evolution of MADRS global score (PP population) 
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Figure 3. Evolution of anxiety scales (PP population) 
TOLERABILITY 
Fifty-eight patients (18%) withdrew from the study, 29 in the tianeptine group and 29 in the 
paroxetine group (p = 0.940). However, reasons for withdrawal were significantly different in 
the two groups (p = 0.001), with more withdrawal for adverse event (19 versus 6) in the 
paroxetine group versus more withdrawals for lack of efficacy (11 versus 4) or non-medical 
reason (11 versus 4) in the tianeptine group. One patient withdrew due to recovery in the 
tianeptine group and two patients were lost to follow up in the paroxetine group. At inclusion, 
only minor and non-significant laboratory abnormalities were reported for recruited patients. 
As the two study products are well-known drugs, no further laboratory measures were taken. 
Tolerability of the two products was good. During the whole study period (including the 
inclusion visit), 204 patients (62%) reported at least one adverse event, 96 (59%) in the 
tianeptine group and 108 (65%) in the paroxetine group. 
Emergent adverse events were reported in 152 patients (46%), with a significantly higher 
frequency (p = 0.026) in the paroxetine group (87 patients, 53%) than in the tianeptine group 
(65 patients, 40%). The most frequently reported emergent adverse events were nausea (7%) 
and headaches (6%) in the tianeptine group versus nausea (15%), headaches (8%), insomnia 
(6%) and dizziness (5%) in the paroxetine group (Table 4). This was confirmed using the 
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AMDP-5 check list where the most frequent emergent symptoms were nausea (T = 7%, P = 
15%) and headaches (T = 10%, P = 10).  
Severe, treatment-related adverse events, despite a low overall incidence, were also more 
frequent in the paroxetine group (seven events: two nausea, headache, malaise, weight increase, 
abdominal pain and bradycardia) than in the tianeptine group (only two events: headache and 
abdominal pain). 
Despite the lack of a dose-tapering procedure, no withdrawal syndrome was reported after 
discontinuation of either drug. However, a post visit was not performed for all the patients and, 
when feasible, was at any time between the end of the 6-week double-blind period and the end 
of the optional continuation period (up to 6 months). Utilising only post visits performed 1 week 
after D42 in patients without immediate switch from the study drug to another antidepressant, 
permitted analysis of barely more than half of the patients (tianeptine: n = 82; paroxetine: n = 
90). For these patients, CGI scores were similar at post visit and complement CHESS did not 
show any major discrepancies in somatic symptoms present 7 days after withdrawal. 
 
Table 4. Most frequent emergent adverse events 
Symptom  Tianeptine (n = 162) Paroxetine (n = 165) 
Overall* 65 (40%) 87 (53%) 
Nausea 11 (7%) 24 (15%) 
Headache 10 (6%) 14 (8%) 
Insomnia 2 (1%) 10 (6%) 
Dizziness 1 (1%) 8 (5%) 
*p = 0.02 (p-values not assessed for individual symptoms). 
Discussion 
This trial was intended to study both the depressive and the anxious components of major 
depressive disorder. Methodological problems were outlined in Section 1. Only moderate to 
severe depressed patients, according to DSM-IV criteria, were included: a minimum rating of 25 
on MADRS was required. As depressive scales, and especially the HDRS, also include anxious 
symptoms, a sub-scale of HDRS (items 1, 2, 7, 8, 10 and 13) presumed to be more specific for 
depressive symptoms was also used with a minimum threshold of 9. Thus, only patients with an 
authentic Major Depression participated in the study.  
In order to limit co-morbid anxious disorders, special attention was given at inclusion to 
psychiatric and therapeutic antecedents. It was decided not to include patients with a previous 
diagnosis of any characterised anxious disorder except General Anxiety Disorder (GAD), but 
only if not within the last year. Moreover, to avoid undiagnosed anxious disorders or severe 
former GAD, major restrictions were made on previous use of anxiolytic treatments, and 
especially benzodiazepines (time of prescription and maximum doses). 
Despite these strict exclusions regarding previous or comorbid anxiety disorders, anxiety scores 
at inclusion remained high, as expected when designing the protocol. These restrictions do not 
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guarantee that no patient suffered previous or concomitant anxious disorder, or that no patient 
later developed a defined anxious disorder, but limit these possibilities both in frequency and in 
severity. 
Thus, patients in the trial can be assumed to be as 'pure depressive' as possible, and anxious 
symptoms can be attributed more to the depressive illness itself than to a possible co- or pre-
morbid anxious pathology. 
The first objective of the study was to compare tianeptine and paroxetine with regard to their 
antidepressant efficacy. The present study demonstrates that both tianeptine and paroxetine are 
effective treatments at 6 weeks in patients suffering from major depression without defined co-
morbid anxious disorder. 
Scores on the different depression scales were very similar throughout the study and no 
difference in efficacy appears between the two treatments. Response rates were high in the two 
groups, with more than 60% of responders whatever the treatment or the evaluation scale 
(MADRS or HDRS), without a significant difference between groups. 
The second objective of the study was to evaluate in this population the effectiveness of 
tianeptine and paroxetine on anxiety. Despite the rigour of the exclusion criteria regarding co-
morbid anxious disorders, mean initial inclusion scores on anxiety scales were quite high (24 for 
HAMA and 18 for BAS), which confirms the importance of anxious symptoms in depressive 
syndrome mentioned in the literature (Hamilton, 1989; Kuhs, 1991). At the end of the study, 
improvements on anxiety scale were highly significant, without any observed difference 
between treatments.  
It was assumed before the trial that depression scores and anxiety scores would be highly 
correlated, making the usual anxiety instruments of low accuracy for the estimation of anxiety 
relief in depression (Riskind et al., 1987; Wetzler and Katz, 1989; Watson et al., 1995a,b). This 
was not confirmed in this study. However, the independence between scales was not fully 
demonstrated (especially for the two Hamilton scales) and the planned factorial analysis was 
conducted to isolate possibly more specific clusters for depression and anxiety. This analysis is 
not yet complete and the results regarding this part of the study will be presented separately in 
extenso. 
Briefly, correlation analysis between anxiety scales and depression scales at D1 were 
undertaken and the coefficients found were rather low, except for the two Hamilton scales 
(HDRS and HAMA) where it was > 0.5. The predictive value of anxiety scales on final MADRS 
score was also poor, and covariance analysis never reached statistical significance. 
The poor correlations observed between anxiety scales and depression scales at inclusion 
suggest that the observed improvement of anxiety is, at least partly, related to actions of the 
treatments on the anxious dimension of the pathology and not merely to an indirect effect linked 
to the improvement of depressive symptoms. As both tianeptine and paroxetine are known 
effective antidepressant drugs and also usually have a positive action on anxious symptoms, this 
lack of observed difference for both depression and anxiety scales is not surprising. 
The tolerability of the two drugs was quite good. The most common adverse events were general 
(mainly headaches) and gastro-intestinal (mainly nausea), consistent with the known side-effect 
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profiles of the two drugs. Very few adverse events were considered severe and none had serious 
consequences for the patients. However, tolerability of tianeptine was slightly but significantly 
better than paroxetine, with less withdrawal for adverse events, less emergent adverse events 
and less severe treatment-related adverse events. 
No withdrawal symptoms after cessation of tianeptine or paroxetine treatment were observed 
in this study. However, methodological problems in the design of the post study visit (only half 
of the patients assessable) limit the validity of this observation. 
Conclusion 
Both 37.5 mg a day of tianeptine and 20 mg a day of paroxetine are safe and effective treatments 
for patients suffering from major depression. Improvements are not only observed in depressive 
symptoms, but also in anxious symptoms with both treatments. Despite onerous requirements 
regarding patient selection, control of co-prescriptions and assessment methods, it was not 
possible to demonstrate whether the improvement in anxious symptoms was linked to the 
general improvement of depressive pathology or was, at least partially, due to a specific action of 
the drugs on anxiety. However, the limited individual correlations between initial anxiety 
symptoms and initial and final depressive symptoms suggest that the anxiety scales used in the 
study are valid tools for this population. It thus appears that both tianeptine and paroxetine 
could have a direct action on anxiety in depressive illness, independently of their overall 
influence on depression itself. However, due to the lack of a placebo control arm, such inferences 
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